Testing a new brain imaging tracer for Parkinson's and related diseases

Plain-English translation of NCT07604116 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage study testing a new diagnostic tool called , which is designed to help doctors see abnormal proteins in the brain that are linked to Parkinson's disease and a related condition called Multiple System Atrophy. The medication is injected before a special brain imaging scan (called a PET scan) that shows where these proteins have accumulated. Researchers want to make sure this new imaging agent is safe and works as expected.

Currently, doctors cannot easily see the abnormal brain proteins that cause these neurological diseases while patients are alive—they can only be confirmed after death. This medication could change that by allowing doctors to diagnose and monitor these conditions earlier and more accurately, which might help patients get treatment sooner.

Do you qualify?

You likely qualify if…

you are at least 40 years old
you have been diagnosed with Parkinson's disease or Multiple System Atrophy (or you are a healthy volunteer with no history of neurological or cognitive disorders)
your organs are functioning adequately, as confirmed by basic medical tests
your current treatment regimen (if any) has been stable for at least 4 weeks with no planned changes
you are willing to follow all study procedures and can use effective contraception during the study

You likely don't qualify if…

you are pregnant or breastfeeding
you have a history of other serious neurological disorders or uncontrolled medical conditions
you have an active infection with hepatitis B, hepatitis C, or HIV
you have a severe allergy to the study medication or cannot tolerate PET/CT or MRI scans (for example, due to claustrophobia)
you have received previous treatments specifically designed to target the abnormal brain proteins this study is investigating

What participation looks like

You will receive an injection of and then have a PET scan to see where the medication travels in your brain and how it behaves over time. You'll also have blood tests and possibly an MRI scan to help doctors understand the medication's safety and how your body processes it. The study involves a small number of visits and is designed as an early safety and feasibility study, so researchers will closely monitor you throughout.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Trial locations(2 sites)

China

Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu

Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality